These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 20524793)

  • 1. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
    Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
    Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
    Bryce A; Ryan CJ
    Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
    Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
    Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
    Evaul K; Li R; Papari-Zareei M; Auchus RJ; Sharifi N
    Endocrinology; 2010 Aug; 151(8):3514-20. PubMed ID: 20534728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H; Garcia JA
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
    Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zibotentan for the treatment of castrate-resistant prostate cancer.
    Shepard DR; Dreicer R
    Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.